Sai Life Q1 FY27 Earnings Call — Analysis (NSE: SAILIFE)
Sai Life's Q1 FY27 revenue rises 12% YoY to ₹553 Cr, driven by 26% CRO growth, as management emphasizes deepening large-pharma FTE collaborations and a multi-modality build-out that sets the stage for a stronger H2.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
Q1FY27 Revenue ₹553 Cr ( +12% YoY ) . New guidance — revenue growth and ebitda margi… 15% to 20% growth, 28% to 30% EBITDA . New story: Deepening Large-Pharma FTE Partnerships .
Results
Revenue ₹553 Cr +12% YoY; CRO segment grew 26% YoY, CDMO 6% YoY; CRO accounted for ~40% of revenue, CDMO ~60%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹553 Cr | +12% | yoy · Q1FY27 · compared to ₹496 Cr in Q1 FY26 |
| CRO Revenue Growth | 26% | +26% | yoy · Q1FY27 · CRO segment YoY growth |
| CDMO Revenue Growth | 6% | +6% | yoy · Q1FY27 · CDMO segment YoY growth |
| CDMO Revenue Share | ~60% | +na | point_in_time · Q1FY27 · of total revenue in Q1 FY27 |
| CRO Revenue Share | ~40% | +na | point_in_time · Q1FY27 · of total revenue in Q1 FY27 |
Guidance
Management reiterated mid-term revenue growth guidance of 15–20% and EBITDA margin range of 28–30%, with FY27 capex of ₹1,100–1,300 Cr on track and H2 FY27 expected to be stronger as new capacity comes online.
What management committed to
- [Sai Life] expects longer-term revenue growth of 15–20% and EBITDA margin of 28–30% over a three-to-five-year period. — 15% to 20% growth, 28% to 30% EBITDA, longer-term (3–5 years)
- FY27 capex will be between ₹1,100 Cr and ₹1,300 Cr. — ₹1,100 crores to ₹1,300 crores, FY27
- [Sai Life] expects H2 FY27 to be stronger than H1 FY27, driven by planned capacity expansion going live. — H2FY27
- [Sai Life] will break ground for a peptide manufacturing facility at its new greenfield site and expects it to be operational in 2028. — FY28
- Total cumulative capex spend on the peptide facility by the time it comes online (end of 2028) will be less than ₹300 Cr. — less than INR300 crores, FY28
- [Sai Life]'s formulation facility will be operationally ready within about six months from August 2026 (i.e., by early Q4 FY27). — Q4FY27
- [Sai Life]'s XDC Center of Excellence will open shortly. — Q2FY27
- At least two large pharmaceutical customers will transition from single-service engagements to integrated discovery models by the end of FY27. — at least two, FY27
- A new large pharma FTE engagement on process development will close by the end of Q2 FY27 and work will commence in Q3 FY27. — Q2FY27
- Two customers will achieve regulatory milestones during FY27, and one will achieve a milestone in Q2 FY28. — two more and one, FY27
Key themes
Deepening large-pharma FTE partnerships and multi-modality expansion
How the narrative shifted
- Deepening Large-Pharma FTE Partnerships: Management frames dedicated FTE development contracts as a structural shift that mirrors how China’s CDMOs scaled, now taking root in India, with early evidence of molecules progressing from FTE discovery all the way to late-phase and commercial.
- Multi-Modality Expansion (Peptides, ADCs, Formulation): Sai is aggressively building capabilities beyond small molecules — commercial peptide facility by 2028, XDC Center of Excellence, and clinical formulation — positioning as a technology-led, multi-modality partner, not just a chemistry shop.
- Capacity-Led Growth Inflection: New capacity is being absorbed faster than expected (discovery lab sold out immediately), and larger commercial capacity coming on stream in H2 FY27 will drive a back-end loaded year, supporting mid-term guidance.
- India as China+1 Diversification Hub: Geopolitical uncertainty and IP concerns are strengthening India’s role in pharma supply chain diversification, creating a sustained tailwind for Indian CRDMOs like Sai.
- Biotech Funding Recovery and Leaner Outsourcing: With 18 US biotech IPOs and large M&A exits, capital is expected to flow into new biotech companies that will be built with even leaner internal capabilities, boosting demand for outsourced discovery and development services.
- Integrated Discovery-to-Commercial Model Traction: The company is transitioning from a single-service provider to an integrated partner that captures a customer across the full lifecycle — discovery, development, and manufacturing — which increases wallet share and relationship durability.
- Lumpiness and Long-Term Orientation: Management repeatedly urges investors to view quarterly performance through a multi-year lens due to inherent business lumpiness, while reaffirming mid-term growth and margin targets.
Operational commentary
- Deepened large-pharma FTE engagements: converted a pilot collaboration with a large pharma into a long-term, high-volume discovery chemistry partnership; another top-tier pharma FTE engagement expanded end-to-end from discovery to commercial.
- Six late-phase molecules added over the last 15 months, five from large pharma clients with ongoing FTE relationships; one customer approval in FY26, two more regulatory milestones expected this FY, one in Q2 FY28.
- 33 active commercial molecules and 14 molecules in late phase; three of the four new commercial contracts for this year already added in Q1, described as decently sized value products.
- New discovery capacity commissioned in Q1 already fully sold out, far ahead of the expected 12–18 month fill timeline.
- Peptide development lab for a top-tier pharma coming online shortly; Center of Excellence expanding to deliver pilot clinical quantities; ground-breaking planned for a commercial peptide facility expected operational in 2028.
- XDC Center of Excellence close to opening, supporting payload-linker conjugation across antibodies, peptides, PROTACs, and oligonucleotides.
- Formulation facility (oral solids, Phase 1–2 clinical supplies) about six months from operational readiness; significant interest from large pharma partners integrated with chemistry services.
- Bidar production block (225 KL) on track for H2 or Q3 FY27; total capacity expansion to 1,150 KL by FY27 end as planned.
- Negotiations underway for another large pharma FTE engagement in process development, expected to close by Q2 FY27 and commence work in Q3 FY27.
- Discovery services integrated delivery now covers ~65% of customers (primarily biotech); aim to transition at least two large pharma customers to integrated models this year.
Analyst Q&A
Q. Has the strengthening of large pharma relationships and IP-driven outsourcing accelerated this year vs last?
Krishna noted that the trend is still early-stage but there is acceleration in both scale and scope; Siva added that five of six new late-phase molecules came from FTE relationships, and one engagement has already become end-to-end, signalling genuine progression.
Q. What drove the conversion of the large CRO customer in Q1, and can you quantify the relationship?
Krishna said multiple customers expanded, not just one, and cited both scale growth and integration progression, but did not provide revenue quantification.
Q. What internal return thresholds do you use before committing the heavy capex, and what would make you slow down?
Siva explained internal hurdle rates higher than company ROCE/ROE, stress-testing of assumptions, and a history of slowing capex when demand slackens, emphasizing a modular approach.
Q. Is there a particular reason for not entering the monoclonal antibodies (mAb) space?
Krishna replied, “We will discuss this strategy at later point.”
Q. What is the contribution of fermentation capacities in the current capex?
Krishna stated, “We are not giving information on fermentation at all.”
Research and educational content only. Not investment advice.